While Amgen Inc. lost its bid to get a quick administrative panel review of AbbVie Inc.'s Humira (adalimumab) patent, it is likely to continue the battle in court.
In a pair of decisions issued Jan. 14, the Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) denied...